Morgan Stanley raised the firm’s price target on Intellia Therapeutics (NTLA) to $15 from $11 and keeps an Equal Weight rating on the shares after the company reported that Lonvo-z met all primary and secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema. Following the positive data, the firm raised its view of the odds of success in HAE to 90% from 60%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target raised to $13 from $7 at Baird
- Intellia Reports Positive Phase 3 Results for HAE Gene Therapy
- Intellia Therapeutics says HAELO trial met primary, secondary endpoints
- Intellia Therapeutics initiates rolling BLA submission for lonvo-z for HAE
- Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained